Simplifying the SNAP-ADAR Tool for Broad Usage in Life Science Research and Drug Discovery

The project aims to simplify the SNAP-ADAR RNA base editing tool into an accessible kit for Life Scientists, enhancing drug discovery and genetic research through efficient editing in mammalian cells.

Subsidie
€ 150.000
2022

Projectdetails

Introduction

RNA base editing is a promising approach to manipulate genetic information in a transient and dosable way, which breaks new ground in basic Life Science research and drug discovery. In a preceding ERC CoG action, we have engineered the SNAP-ADAR tool, which allows for the particularly precise, efficient, and programmable adenosine-to-inosine RNA base editing.

Challenges

However, the broad usage of this tool is somewhat hampered by the need for designing the chemically modified guideRNAs. This currently includes some peptide bond-forming chemistry and nucleic acid gel purification.

Objectives

In this PoC action, we aim to simplify the tool to make it available for a larger section of the Life Science community. Specifically, we aim to:

  1. Simplify the chemistry and the compounds to such an extent that a SNAP-ADAR kit is obtained.
  2. Enable Life Scientists to perform the required chemistry without special equipment or chemistry skills.
  3. Include a reliable and simple protocol to perform efficient and precise editing reactions in mammalian primary cells.

Commercial Potential

Profit could particularly be generated from the selling of the chemically stabilized guideRNAs. We envision that the product would find application in:

  • The modulation of protein function, such as signaling cues and metabolic pathways.
  • Target screening and target validation in drug discovery efforts, which are currently ongoing in the field of RNA base editing.

Future Steps

The action also contains an analysis of the IP landscape, and at the later stage of the action, we aim to involve industrial partners for commercialization.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-6-2022
Einddatum30-11-2023
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • EBERHARD KARLS UNIVERSITAET TUEBINGENpenvoerder

Land(en)

Geen landeninformatie beschikbaar

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

RNA-based gene writing in human cells

SCRIBE aims to develop innovative RNA-based gene writing strategies using CRISPR and retrotransposons to enhance gene transfer efficacy and safety for research and therapeutic applications.

€ 1.999.465
ERC Starting...

Profile nucleases and Repurpose Off-Targets to Expand Gene Editing

The PROTÉGÉ project aims to enhance gene editing safety and diversity by profiling programmable nucleases and exploring off-target effects for improved precision in genetic therapies.

€ 1.141.779
ERC Starting...

Conjugation of NAD-capped RNAs to proteins by ADP-ribosyltransferases to generate RNA therapeutics

This project aims to develop RNAylated proteins as innovative RNA therapeutics by establishing design principles and delivery strategies to regulate cellular processes, including targeting the p53 protein.

€ 1.499.162
ERC Starting...

Chemical Tools for Transcriptome-wide Analysis and Modulation of RNA

The RiboChem program aims to develop innovative chemical tools to explore RNA functions and riboswitches, enhancing understanding and targeting for antibiotic development.

€ 1.500.000
ERC Starting...

Expanding the genome editing toolbox by rational reprogramming of tyrosine recombinase DNA specificities

EditYR aims to develop a programmable tyrosine recombinase platform for efficient, precise integration of large DNA cargo into genomes, enhancing gene therapy capabilities for genetic diseases.

€ 1.599.500

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system

The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.

€ 2.988.377
EIC Pathfinder

New Prime Editing and non-viral delivery strategies for Gene Therapy

This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.

€ 4.406.097